Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Synthesis Anti Tuberculosis and Antiviral Activityof Novel 2 isonicotinoylhydrazono 5 arylidene 4 thiazolidinones — Esra Tatar (2010) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Synthesis Anti Tuberculosis and Antiviral Activityof Novel 2 isonicotinoylhydrazono 5 arylidene 4 thiazolidinones
Shared by
De Clercq Erik
KU Leuven
Synthesis Anti Tuberculosis and Antiviral Activityof Novel 2 isonicotinoylhydrazono 5 arylidene 4 thiazolidinones
Article
2010
en
Authors
+7 more
ET
Esra Tatar
İK
İlkay Küçükgüzel
ŞK
Ş. Güniz Küçükgüzel
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2010
Synthesis, Anti-Tuberculosis and Antiviral Activity of Novel 2-isonicotinoylhydrazono-5-arylidene-4-thiazolidinones
Esra Tatar
,
İlkay Küçükgüzel
,
Ş.Güniz Küçükgüze
,
Feyza Yılmaz-Demircan
,
De Clercq Erik
,
Graciela Andreï
,
Robert Snoeck
,
Christophe Pannecouque
,
Fikrettin Şahιn
,
Ömer Faruk Bayrak
Article
2009
Synthesis and anti-HIV activity evaluation of novel N′-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides
Peng Zhan
,
Hongbing Liu
,
Xinyong Liu
,
Yan Wang
,
Christophe Pannecouque
,
Myriam Witvrouw
,
De Clercq Erik
Article
2004
Synthesis and Antiviral Activity Assay of Novel (E)‐3′,5′‐Diamino‐5‐(2‐bromovinyl)‐2′,3′,5′‐trideoxyuridine
Iván Lavandera
,
Susana Fernández
,
Miguel Ferrero
,
De Clercq Erik
,
Vicente Gotor
Article
2006
Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds
Umashankar Das
,
Jane Alcorn
,
Anuraag Shrivastav
,
Rajendra K. Sharma
,
De Clercq Erik
,
Jan Balzarini
,
Jonathan R. Dimmock
Article
2003
Synthesis and Antiviral Activity Assay of Novel (<i>E</i>)-3′,5′-Diamino-5-(2-bromovinyl)-2′,3′,5′-trideoxyuridine
Iván Lavandera
,
Susana Fernández
,
Miguel Ferrero
,
De Clercq Erik
,
Vicente Gotor
Discussion(0)
No comments yet. Be the first to comment.